All news

HC Wainwright reiterates Buy on UroGen, keeps $75 target

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

HC Wainwright & Co. reiterated a Buy rating on UroGen Pharma and maintained its $75 price target. Analyst consensus stands at seven Buy, one Hold and no Sell ratings, with a $60 target versus a $45 share price. GuruFocus flags the stock as 9.5% overvalued against a $30.70 intrinsic value.

Read original source

URGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.